0.45
0.45 (0%)
As of Apr 17, 2025
Tenaya Therapeutics, Inc. [TNYA]
Source:
Company Overview
Tenaya Therapeutics, Inc is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Heart disease is the leading cause of death in the world, representing an estimated 32% of all global fatalities.
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | (650) 825-6990 |
| Industry | manufacturing |
| CEO | Faraz Ali, M.B.A. |
| Website | www.tenayatherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-115.9 |
| Net Income | $-111.1 |
| Net Cash | $-41.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -76.5% |
| Profit as % of Stockholder Equity | -119.7% |
Management Effectiveness
| Return on Equity | -119.7% |
| Return on Assets | -92.7% |
| Turnover Ratio | |
| EBITA | $-115.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $119.9 |
| Total Liabilities | $27.1 |
| Operating Cash Flow | $-90.5 |
| Investing Cash Flow | $1.1 |
| Financing Cash Flow | $47.7 |
